

Working together to build effective & efficient regulatory systems

Improving affordable & equitable access to quality-assured medical products




DCVMN-AGM2022 Session on Innovation in Regulatory & PQ


Rogério Gaspar | Director, Department of Regulation and Prequalification (RPQ)

WHO's Regulatory Strategic Priorities: 2019-2023











Reinforce and expand WHO prequalification & product risk assessment

Increase the impact of WHO regulatory support activities


These strategic guide WHO regulatory activities

- ✓ Benchmarking and technical assistance to address regulatory gaps
- Promoting regulatory convergence, harmonization, work-sharing and reliance mechanisms
- ✓ Improving countries' ability to carry out risk-based post-marketing surveillance to securing supply chains against SF products
 - Includes strengthening national quality laboratories
- ✓ Broaden the prequalification programme
- ✓ Leverage political attention and commitment to advance accountability
- ✓ Promote and support sustainable and quality-assured local production through technical assistance

https://www.who.int/medicines/news/2019/strong-reg-systems-to-reach-UHC/en/

Report of an Independent External Review - June 2019

4A WHO PQP has a Return on Investment of 30-40 to 1






Snapshot of donations/allocations (15 Aug 2022)



4926 regulatory approvals in 175 countries/territories



Revised guidance EUL document* 30 March 2022

- Posted on 30 March 2022, following discussions with regulators and with the WHO R&D Blueprint Team
- The revised document
- Acknowledges applications for EUL based on *immunobridging*
- Indicates that careful choice of comparators is important
- Indicates that additional nonclinical and immunogenicity data may be required
- Indicates that demonstration of efficacy by in-deployment clinical trials or of (more likely to happen in practice) effectiveness by post-deployment observational studies will also be needed as a post-listing commitment

Avoids being too prescriptive

Is aligned with the

- revised WHO Target Product Profiles (TPP) for COVID-19 vaccines
- draft R&D Blueprint Team "Framework" document

* Considerations for evaluation of COVID-19 vaccines: Points to consider for manufacturers of COVID-19 vaccines. Revised version, 30 March 2022

(https://extranet.who.int/pqweb/sites/default/files/documents/Considerations Assessment Covid-19 Vaccines_v30March2022.pdf)



Immunobridging WHO EUL requirements updated March 2022

Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC)

1. <u>https://www.who.int/news/item/17-06-2022-</u> interim-statement-on--the-composition-of-current-COVID-19-vaccines


- 2. International Coalition of Medicines Regulatory Authorities; <u>https://icmra.info/drupal/en/covid-19/30june2022</u>
- 3. <u>https://www.gov.uk/government/news/first-</u> <u>bivalent-covid-19-booster-vaccine-approved-by-</u> <u>uk-medicines-regulator</u>

The WHO TAG-CO-VAC continues to monitor and assess the **evidence on the genetic and antigenic characteristics of SARS-CoV-2 Variants of Concern (VOC)**, including descendent lineages of VOCs.



In their latest statement¹, TAG-CO-VAC advised that it may be prudent for manufacturers seeking to pursue an updated composition of current COVID-19 vaccines, to seek to **achieve broader immunity** against circulating and emerging variants, while **retaining protection against severe disease and death**

 viruses or sequences closely related to Omicron BA.1 are some of the most antigenically distant from the index virus



The USA FDA issued a recommendation for COVID-19 vaccine composition to include Omicron BA.5 in an attempt to **increase and extend protection by better matching** the vaccine composition with circulating variants

• mRNA vaccines which include BA.5 may be available in the USA by the Northern Hemisphere fall, pending regulatory approval.




A statement from ICMRA² indicates that **adapted mRNA vaccines**, which **incorporate an Omicron variant**, can increase and extend protection, when **used as a booster dose**, but gives no indication as to which Omicron lineage should be included.



The MHRA has approved³ the use of the Moderna bivalent vaccine product (index virus + Omicron BA.1) as a booster dose in the UK.








Source: Global Health Centre - Graduate Institute Geneva https://www.knowledgeportalia.org/covid19-vaccine-manufacturing



Local Production and Assistance





Global status of national regulatory systems, April 2022




GOAL of WHA Resolution 67.20


Nigeria and Egypt announced as ML 3 in March 2022

ML: (regulatory system) maturity level

How does the collaborative procedures work?




CRP in facilitating in-country regulatory approval of medical products





Reliance is "implanted" in facilitated regulatory pathways





Benefits of WHO-Listed Authority (WLA) framework



Enable efficient use of regulatory resources

by providing a robust framework to promote trust, confidence and reliance Encourage continuous improvement of regulatory systems and

regulatory convergence

Help procurement decisions

on medical products by UN and other agencies, as well as countries (especially LMICs)

Contributes to WHO PQ programme

by expanding the pool of trusted regulatory authorities

Fosters health equity

by enabling an environment for innovation and local production, and accelerating access to medical products Access to quality medicines and other health products requires **an integrated approach** with all stakeholders




Rogério Gaspar | Director, Department of Regulation and Prequalification (RPQ)

Back-up slides




Report of an Independent External Review - June 2019

5A 340-400 million more patients are accessible thanks to resources freed up by PQ




Assuming a fixed donor market size for all products, calculated the share of the market represented by savings (i.e. the freed up budget). Treatment cost/year price only includes price of the product itself.






WHO Emergency Use Listing process





Clinical evidence is required for variant vaccines to be authorized and implemented in programmes

COVID-19 current vaccine development pipeline - Variants*



Norld Health

*Adapted from Cepi 5 Aug 22 - Based on publicly available information from vaccine candidates based on variants **Broadly protective Beta coronavirus

Variant-containing COVID-19 vaccines

As of 31 August 2022

World Health Organization

Manufacturer	Variant-containing vaccine	Publicly available data		
		Animal model data	Clinical data	
Moderna	mRNA1274.211 (Beta) monovalent		Yes ^{1,2}	
	mRNA1274.211 (Beta) bivalent		Yes ^{1,2}	
	mRNA1274.214 (Omicron BA.1) bivalent	Yes ^{3,4}	Yes ⁵	
	mRNA1274.214 (Omicron BA.5) bivalent	-	-	
Pfizer	BNT162b2 (Omicron BA.1) monovalent	Yes ⁶	Yes ⁶	
	BNT162b2 (Omicron BA.1) bivalent	Yes ⁶	Yes ⁶	
	BNT162b2 (Omicron BA.5) bivalent	Yes ⁶	-	
Sanofi/GSK	Beta monovalent		Yes*	
	Beta + D614 bivalent		Yes*	

World Health Organization

*Shared with WHO; not in public domain Under development: Novavax Omicron-containing product; Sinopharm Omicron-containing product



Adding variant adapted vaccines to portfolios as boosters potential additional operational complexity for countries



INDICATIVE // NON-EXHAUSTIVE

DATA AS OF AUGUST 15, 2022

SII - Covishield only 📕 AstraZeneca - Vaxzevria only 📗 Both

Countries & economies using available vaccines, Cumulative number of different vaccines products used

AstraZeneca - Vaxzevria / SII - Covishield			50	181
Pfizer BioNTech - Comirnaty				172
Moderna - mRNA-1273			123	
Janssen - Ad26			123	
Beijing CNBG - BBIBP-CorV		101		
Gamaleya - Sputnik V		70		
Sinovac - CoronaVac	6	8		
Bharat - Covaxin	33			
Novavax - Covavax	33			
Bharat - Covaxin	33			
CanSino - Convidecia	28			
Adbala	4			
Soberana02	4			
CIGB - CIGB-66	4			
Wuhan CNBG - Inactivated	3			
Anhui ZL - Zifivax	3			
Julphar - Hayat-Vax	3			
RIBSP - QazVac	3			
SRCVB - EpiVacCorona	2			
RIBSP - QazCovid	2			
Biological E - Corbevax	1			
Chumakov - Covi-Vac	1			
IMB - Covidful	1			
Shifa - COVIran Barakat	1			
Turkovac	1			
Zydus - ZyCov-D	1			

12 countries and economies are using 1 vaccine; 206 are using 2 or more vaccines¹

1. World Bank classification (2021) of 218 economies. Note: The term country, used interchangeably with economy, does not imply political independence but refers to any territory for which authorities report separate social or economic statistics.

21 Source: Our World in data, WHO COVID-19 dashboard, Government websites; Press research